Recent News

• 04.16.2025 - BDD’s OralogiK™ Technology Powers Advancement of A Once-Daily Anxiety Treatment
• 04.09.2025 - Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
• 04.03.2025 - Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
• 03.26.2025 - Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
• 03.04.2025 - Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
• 02.03.2025 - John Vandermosten
• 02.03.2025 - Boobalan Pachaiyappan

Recent Filings

• 04.15.2025 - PRE 14A Other preliminary proxy statements
• 04.09.2025 - 8-K Current report
• 04.09.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2025 - EX-99.1 EX-99.1
• 03.26.2025 - 8-K Current report
• 03.04.2025 - EX-99.1 EX-99.1
• 03.04.2025 - 8-K Current report
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities